Skip to main content
SpringerLink
Log in
Book cover

New Trends in the Molecular and Biological Basis for Clinical Oncology pp 3–28Cite as

HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase

  • Conference paper

  • 353 Accesses

Abstract

We investigated the effect of HER2 overexpression on resistance to aromatase inhibitor letrozole in MCF-7 breast cancer cells stably expressing cellular aromatase (MCF-7/CA). Forced expression of HER2 in MCF-7/CA cells by infection with retroviral vector showed increased Akt and MAPK phosphorylation and phosphorylation of estrogen receptor (ER) a. on Ser118 and Serl67. MCF-7/CA cells overexpressing HER2 (MCF-7/CA pBMN- HER2) showed more than 2 fold higher level of ER-mediated transcription activity upon androstenedione treatment as compared to vector control MCF-7/CA (MCF-7/CA pBMN-vec) cells and letrozole co-treatment did not effectively block androstenedione-induced transcription. Inhibition of Akt and MAPK by LY294002 and UO126 in MCF-7/CA pBMN-HER2 cells, respectively, resulted in the reduction of androstenedione-induced transcription activities comparable to those of MCF-7/CA pBMN-vec cells. MCF-7/CA pBMN-HER2 cells showed increased proliferation in the medium containing charcoal-stripped serum supplemented with androstenedione as compared to MCF-7/CA pBMN-vec cells. Moreover, co-treatment of letrozole could not efficiently abrogate androstenedione-mediated cell proliferation in MCF-7/CA pBMN-HER2 cells. MCF-7/CA pBMN-HER2 cells were also shown to be resistant to letrozole-induced apoptosis. Aromatase activities of both MCF-7/CA pBMN-HER2 and MCF-7/CA pBMN-vec cells were reduced to the similar basal levels by letrozole treatment, suggesting that resistance to letrozole is not conferred by the resistance of aromatase enzyme itself to letrozole. Chromatin immunopreciptation assays revealed that MCF-7/CA pBMN-HER2 cells showed ligand-independent association of estrogen receptor (ER) α, coactivators AIB1 and CBP to the promoter region of pS2 gene. Upon androstenedione treatment, there were increased associations of ERa, AIB1 and CBP with pS2 promoter in MCF-7/CA pBMN-HER2 cells as compared to MCF-7/CA pBMN-vec cells. These results suggest that recruitment of coactivator complexes to estrogen-responsive promoter by HER2 overexpression may play a role in developing letrozole resistance through upregulation of estrogen-responsive genes and increased cell survival and proliferation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340–1349

    PubMed  CAS  Google Scholar 

  • Balthazart J, Baillien M, Charlier TD, Ball GF (2003) Calcium-dependent phosphorylation processes control brain aromatase in quail. Eur J Neurosci 17: 1591–1606

    Article  PubMed  CAS  Google Scholar 

  • Balthazart J, Baillien M, Ball GF (2001) Phosphorylation processes mediate rapid changes of brain aromatase activity. J Steroid Biochem Mol Biol 79: 261–277

    Article  PubMed  CAS  Google Scholar 

  • Bellino FL, Holben L (1989) Placental estrogen synthetase (aromatase): evidence for phosphatase-dependent inactivation. Biochem Biophys Res Commun 162: 498–504

    Article  PubMed  CAS  Google Scholar 

  • Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85–95

    Article  PubMed  CAS  Google Scholar 

  • Berry M, Nunez AM, Chambon P (1989) Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86: 1218–1222

    Article  PubMed  CAS  Google Scholar 

  • Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753–758

    Article  PubMed  CAS  Google Scholar 

  • Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, Zhao Y, Hinshelwood MM, Ito Y, Simpson ER (1997) Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 61: 133–139

    Article  PubMed  CAS  Google Scholar 

  • Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER (1993) A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77: 1622–1628

    Article  PubMed  CAS  Google Scholar 

  • Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83: 1142–1152

    Article  PubMed  CAS  Google Scholar 

  • Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276: 9817–9824

    Article  PubMed  CAS  Google Scholar 

  • Coutts AS, Murphy LC (1998) Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58: 4071–4074

    PubMed  CAS  Google Scholar 

  • Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453–461

    PubMed  CAS  Google Scholar 

  • Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–3816

    PubMed  CAS  Google Scholar 

  • Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Janicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2003) Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63: 6523–6531

    PubMed  CAS  Google Scholar 

  • Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, VanDyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623–18632

    Article  PubMed  CAS  Google Scholar 

  • Fraser A, Evan G (1996) A license to kill. Cell 85: 781–784

    Article  PubMed  CAS  Google Scholar 

  • Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 16: 1647–1655

    Article  PubMed  CAS  Google Scholar 

  • Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (1974) Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38: 476–479

    Article  PubMed  CAS  Google Scholar 

  • Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220–1226

    Article  PubMed  CAS  Google Scholar 

  • Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP (1999) Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A 96: 4686–4691

    Article  PubMed  CAS  Google Scholar 

  • Iwase H (2003) Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer 10: 89–96

    Article  PubMed  Google Scholar 

  • Janes PW, Daly RJ, deFazio A, Sutherland RL (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9: 3601–3608

    PubMed  CAS  Google Scholar 

  • Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491–1494

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G (2000) Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer 1 Suppl 1: S15–18

    Article  Google Scholar 

  • Kinoshita Y, Chen S (2003) Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Cancer Res 63: 3546–3555

    PubMed  CAS  Google Scholar 

  • Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60: 5887–5894

    PubMed  CAS  Google Scholar 

  • Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T, Saijo N (1999) Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol Rep 6: 33–37

    PubMed  CAS  Google Scholar 

  • Leonessa F, Boulay V, Wright A, Thompson EW, Brunner N, Clarke R (1992) The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. Acta Oncol 31: 115–123

    Article  PubMed  CAS  Google Scholar 

  • Litherland S, Jackson IM (1988) Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 15: 183–194

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG (1995) MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34: 97–117

    Article  PubMed  CAS  Google Scholar 

  • Long BJ, Jelovac D, Thiantanawat A, Brodie AM (2002) The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 8: 2378–2388

    PubMed  CAS  Google Scholar 

  • Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM (1998) The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Bio ehern Mol Biol 67: 293–304

    Article  CAS  Google Scholar 

  • Mahendroo MS, Mendelson CR, Simpson ER (1993) Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 268: 19463–19470

    PubMed  CAS  Google Scholar 

  • Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P (1982) Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895–7903

    Article  PubMed  CAS  Google Scholar 

  • Means GD, Kilgore MW, Mahendroo MS, Mendelson CR, Simpson ER (1991) Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol Endocrinol 5: 2005–2013

    Article  PubMed  CAS  Google Scholar 

  • Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F (1996) Tyrosine kinase/p21 ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. Embo J 15: 1292–1300

    PubMed  CAS  Google Scholar 

  • Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F (1998) Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. Embo J 17: 2008–2018

    Article  PubMed  CAS  Google Scholar 

  • Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887–8895

    PubMed  CAS  Google Scholar 

  • Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606

    PubMed  CAS  Google Scholar 

  • Naftolin F, Ryan KJ, Davies IJ, Reddy VV, Flores F, Petro Z, Kuhn M, White RJ, Takaoka Y, Wolin L (1975) The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res 31: 295–319

    PubMed  CAS  Google Scholar 

  • Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA,et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37–43

    Article  PubMed  CAS  Google Scholar 

  • Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19: 3159–3167

    Article  PubMed  CAS  Google Scholar 

  • Perel E, Blackstein ME, Killinger DW (1982) Aromatase in human breast carcinoma. Cancer Res 42: 3369s–3372s

    PubMed  CAS  Google Scholar 

  • Riese DJ, 2nd, Stern DF (1998) Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41–48

    Article  PubMed  Google Scholar 

  • Robinson-Rechavi M, Escriva Garcia H, Laudet V (2003) The nuclear receptor superfamily. J Cell Sci 116: 585–586

    Article  PubMed  Google Scholar 

  • Sasano H, Harada N (1998) Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev 19: 593–607

    Article  PubMed  CAS  Google Scholar 

  • Seralini G, Moslemi S (2001) Aromatase inhibitors: past, present and future. Mol Cell Endocrinol 178: 117–131

    Article  PubMed  CAS  Google Scholar 

  • Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ (2000) Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141:396–405

    Article  PubMed  CAS  Google Scholar 

  • Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926–935

    Article  PubMed  CAS  Google Scholar 

  • Shozu M, Sumitani H, Murakami K, Segawa T, Yang HJ, Inoue M (2001) Regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated protein kinase. J Steroid Biochem Mol Biol 79: 61–65

    Article  PubMed  CAS  Google Scholar 

  • Shozu M, Zhao Y, Simpson ER (1997) Estrogen biosynthesis in THP1 cells is regulated by promoter switching of the aromatase (CYP19) gene. Endocrinology 138: 5125–5135

    Article  PubMed  CAS  Google Scholar 

  • Shozu M, Simpson ER (1998) Aromatase expression of human osteoblast-like cells. Mol Cell Endocrinol 139: 117–129

    Article  PubMed  CAS  Google Scholar 

  • Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I, Coombes RC (1989) Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 49: 2588–2591

    PubMed  CAS  Google Scholar 

  • Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538–541

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A,et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712

    Article  PubMed  CAS  Google Scholar 

  • Thiantanawat A, Long BJ, Brodie AM (2003) Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63: 8037–8050

    PubMed  CAS  Google Scholar 

  • Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272: 17907–17911

    Article  PubMed  CAS  Google Scholar 

  • Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y (1997) Bivalence of EGF-like ligands drives the ErbB signaling network. Embo J 16: 4938–4950

    Article  PubMed  CAS  Google Scholar 

  • Tzahar E, Yarden Y (1998) The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377: M25–37

    PubMed  CAS  Google Scholar 

  • Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL (2004) Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505–24513

    Article  PubMed  CAS  Google Scholar 

  • Utsumi T, Harada N, Maruta M, Takagi Y (1996) Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J Clin Endocrinol Metab 81:2344–2349

    Article  PubMed  CAS  Google Scholar 

  • Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (LY294002). J Biol Chem 269: 5241–5248

    PubMed  CAS  Google Scholar 

  • Yamauchi H, O’Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518–2525

    PubMed  CAS  Google Scholar 

  • Yue W, Wang JP, Conaway MR, Li Y, Santen RJ (2003) Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 86: 265–274

    Article  PubMed  CAS  Google Scholar 

  • Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137: 5739–5742

    Article  PubMed  CAS  Google Scholar 

  • Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S (1996) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59: 163–171

    Article  PubMed  CAS  Google Scholar 

  • Zhou D, Wang J, Chen E, Murai J, Siiteri PK, Chen S (1993) Aromatase gene is amplified in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 46: 147–153

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232

    Incheol Shin, E. Shizen Wang & Carlos L. Arteaga

  2. Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232

    Todd Miller & Carlos L. Arteaga

  3. Department of Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, 37232

    Carlos L. Arteaga

  4. Department of Life Science, Hanyang University, Seoul, 133-791, Korea

    Incheol Shin

Authors
  1. Incheol Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Todd Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Shizen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos L. Arteaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Oral Pathology and Diagnosis, Showa University School of Dentistry, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan

    Tetsuhiko Tachikawa D.D.S., Ph.D. (Professor and Chairman) (Professor and Chairman)

  2. Department of Microbiology, Showa University School of Pharmaceutical Sciences, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan

    Kiyoshi Nose Ph.D. (Professor and Chairman) (Professor and Chairman)

  3. Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan

    Tohru Ohmori M.D., Ph.D. (Associate Professor) (Associate Professor)

  4. Division of Allergology and Respiratory Medicine, Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

    Mitsuru Adachi M.D., Ph.D. (Professor and Chairman) (Professor and Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer

About this paper

Cite this paper

Shin, I., Miller, T., Wang, E.S., Arteaga, C.L. (2009). HER2 Overexpression Attenuates the Antiproliferative Effect of Aromatase Inhibitor in MCF-7 Breast Cancer Cells Stably Expressing Aromatase. In: Tachikawa, T., Nose, K., Ohmori, T., Adachi, M. (eds) New Trends in the Molecular and Biological Basis for Clinical Oncology. Springer, Tokyo. https://doi.org/10.1007/978-4-431-88663-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-88663-1_1

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-88662-4

  • Online ISBN: 978-4-431-88663-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation